View Mobile No.

our range

Hepatitis Medicine

Leading Manufacturer of sofokast-plus tablets. sofosbuvir 400mg & daclatasvir 60mg, ledikast tablets. ledispasvir 90mg & sofosbuvir 400mg, velakast tablets sofosbuvir 400mg & velpatasvir 100mg, sofokast tablets.sofosbuvir 400mg and dacikast-60 tablets.daclatasvir 60mg from Mumbai.
  • Sofokast-Plus Tablets. Sofosbuvir 400mg & Daclatasvir 60mg
  • Sofokast-Plus Tablets. Sofosbuvir 400mg & Daclatasvir 60mg
Sofokast-Plus Tablets. Sofosbuvir 400mg & Daclatasvir 60mg

Sofokast-Plus Tablets. Sofosbuvir 400mg & Daclatasvir 60mg

Rs 6,500  / BottleGet Best Price

Minimum Order Quantity: 1 Bottle

Packaging Size1X28
Strength400mg/60mg
CompositionSofosbuvir 400mg & Daclatasvir 60mg
TreatmentHepatitis C virus infection (HCV)
Prescription/Non prescriptionPrescription
BrandSofokast-Plus
ManufacturerNatco Pharma Ltd
FormTablet
Shelf life2 years
Therapeutic UsesHepatitis C virus infection (HCV)
We are manfacturer,trader & supplier of Sofokast-Plus Tablets. Sofokast-Plus Tablets sofosbuvir 400mg & daclatasvir 60mg are hostile to viral medicine Sofokast-Plus  tablets are single measurements treatment, it is a doctor prescribed medication utilized by the patients just under the information of restorative expert who are all around rehearsed Daclatasvir isn't utilized alone, for better activity it ought to be joined with Sofosbuvir tablet. In some condition Sofokast-Plus is joined with ribavirin, a hostile to viral pharmaceutical utilized as a part of decompensated (Child Pugh B or C) cirrhosis
PRESCRIBED FOR

The primary sign of Sofokast-Plus  is; This mix tablets are utilized to treat the constant hepatitis C viral disease caused by genotype I or III The significant restriction happened while utilizing Sofokast-Plus  tablets are lessening of steady virological reaction rate in hepatitis C genotype I or III contaminated patients.

PHARMACOLOGY

The activity of Sofokast-Plus  tablets are occurred by involving in some mechanism;

SOFOSBUVIR

 

Sofosbuvir containing sofosbuvir has hostile to hepaciviral movement, which is specifically acting medication displays its activity by disallowing NS5B RNA dependent RNA polymerase protein; fundamental for hepatitis viral duplication. Sofosbuvir is processed to frame uridine triphosphate, a fundamental dynamic metabolite which uncovered a hostile to viral action. The mixture of this dynamic metabolite into hepatitis viral RNA with the assistance of NS5B polymerase and causes viral chain cessation

DACLATASVIR

 

Daclatasvir containing Daclatasvir removes hostile to viral action by restricting NS5A protein which is needful in viral generation and virion collection
SOFOKAST - PLUS SIDE EFFECTS 

Side effects occurred in Sofokast-Plus tablet receiving patients such as; Fatigue Headache Insomnia Nausea Pruritus Asthenia Anemia Loss of appetite Flu like syndrome Pyrexia Diarrhea Rash Neutropenia Myalgia Irritability Pancytopenia Increase of creatine kinase, bilirubin, lipase, AST & ALT HBV reoccurrence may occurs Serious bradycardia while combining with amiodarone



Additional Information:

  • Production Capacity: Large
  • Delivery Time: Immediate
  • Packaging Details: 28 tablets in a bottle

View Complete details

get quoterequest a call back
Ledikast Tablets. Ledispasvir 90mg & Sofosbuvir 400mg

Ledikast Tablets. Ledispasvir 90mg & Sofosbuvir 400mg

Rs 5,500  / BottleGet Best Price

Minimum Order Quantity: 1 Bottle

Packaging Size1X28
Strength90mg/400mg
CompositionLedispasvir 90mg & Sofosbuvir 400mg
TreatmentHepatitis C virus infecton (HCV)
Prescription/Non prescriptionPrescription
BrandLedikast
ManufacturerNatco Pharma Ltd
FormTablet
Shelf life2 years
Therapeutic UsesHepatitis C virus infecton (HCV)
We are manfacturer,trader & supplier of Ledikast Tablets.Ledikast tablet contains Ledispasvir 90mg & Sofosbuvir 400mg should be used for both adults & pediatric patients with the age of 12 years or older or weight of at least 35kg. Used for; Genotype I, 4, 5, or 6 with compensated cirrhosis or without cirrhosis Genotype 1 infection with compensated cirrhosis or without cirrhosis Liver transplantation condition, genotype 1 with decompensated cirrhosis by use of ribavirin Genotype 1 or 4 without cirrhosis or with compensated cirrhosis by use of ribavirin Pediatric patients, HCV infection related to genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis.
DOSAGE

The usual advised dose of Ledikast is one tablet should be administered as once a day. In HIV-1 co infected patients, Ledifos dosage consideration is; Patient without cirrhosis: (adult or pediatric of 12 years of age or older with genotype I, IV, V or VI Chronic HCV) The prescribed dose of Ledikast is one tablet should be taken orally as a single dose for 12 weeks.

Genotype I

Without cirrhosis or compensated cirrhosis: Ledikast should be taken alone as a single dose followed for 12 weeks

Therapy experienced without cirrhosis:Ledikast should be taken as a single agent for once a day for 12 weeks

Therapy experienced with compensated cirrhosis: Ledikast tablet should be used for 24 weeks
In decompensated cirrhosis: Ledifos should be combined with ribavirin to be used, followed for 12 weeks

Genotype I to IV

 

In liver transplantation patients with compensated cirrhosis or without cirrhosis: Ledikast tablet should be combined with ribavirin for 12 weeks.
Genotype IV, V or VI :
Ledikast tablets should be administered alone for 12 weeks for Without cirrhosis or with compensated cirrhosis patients: On the basis of body weight the dose of ribavirin should be calculated <75kg: 1000mg; ≥75kg: 1200mg Ribavirin should be administered with food. Ledikast should be administered with or without food.
LEDIKAST SIDE EFFECTS 

Elevation of bilirubin Elevation of lipase Elevation of creatine kinase Severe bradycardia HBV reactivation Chest pain Dizziness Trouble in breathing Fatigue Headache Nausea Diarrhea Insomnia

 



Additional Information:

  • Production Capacity: Large
  • Delivery Time: Immediate
  • Packaging Details: 28 tablets in a bottle

View Complete details

get quoterequest a call back
Velakast Tablets Sofosbuvir 400mg & Velpatasvir 100mg

Velakast Tablets Sofosbuvir 400mg & Velpatasvir 100mg

Rs 8,200  / BottleGet Best Price

Minimum Order Quantity: 1 Bottle

Packaging Size1x28
Strength400mg/100mg
CompositionSofosbuvir 400mg & Velpatasvir 100mg
TreatmentHepatitis C virus infection (HCV)
Prescription/Non prescriptionPrescription
BrandVelakast
ManufacturerNatco Pharma Limited
FormTablet
Shelf life2 years
Therapeutic UsesHepatitis C virus infection (HCV)
We are manfacturer,trader & supplier of Velakast Tablets. Velakast tablet contains Sofosbuvir 400mg & Velpatasvir 100mg is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. Velakast is the FDA approved product, which is used in chronic HCV condition. Velakast should be used in genotype I, II, III, IV, V or VI associated hepatitis C viral infections. is the FDA approved product, which is used in chronic HCV condition. Velakast should be used in genotype I, II, III, IV, V or VI associated hepatitis C viral infections.
DOSAGE BEFORE THE TREATMENT

Examine the patients thoroughly, before initiating the treatment with HCV anti-viral agents. Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs. Velakast tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of Velpanat; The usual recommended dose of Velakast  is, one tablet should be administered orally as a single dose. Velakast  tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir

WORKS

 

Sofosbuvir is a NS5B protein inhibitor, protein is essential for viral production. Sofosbuvir is a prodrug form, which get converted into active uridine triphosphate form which is required for anti-viral activity. This dynamic active moiety is get inserted into HCV RNA with the help of NS5B polymerase and leads as chain eliminator. Velpatasvir is pharmacologically acts as NS5A inhibitor; this protein is required for HCV viral production. Velpatasvir is involved its action in viral production process.
VELAKAST UNFAVORABLE EFFECTS 

Serious bradycardia occurs due to concomitant use of Velakast with amiodarone. Insomnia Irritability Headache Fatigue Nausea Asthenia

LAB ABNORMALITIES

Lipase elevation Elevation of creatine kinase Elevation of bilirubin levels

POST MARKETING EFFECTS

Cardiac disorders Rashes Angioedema



Additional Information:

  • Production Capacity: Large
  • Delivery Time: Immediate
  • Packaging Details: 28 tablets in a bottle

View Complete details

get quoterequest a call back
Sofokast Tablets.Sofosbuvir 400mg

Sofokast Tablets.Sofosbuvir 400mg

Rs 4,000  / BottleGet Best Price

Minimum Order Quantity: 1 Bottle

Packaging Size1X28
Strength400MG
CompositionSofosbuvir 400mg
TreatmentHepatitis C virus infection ( HCV)
Prescription/Non prescriptionPrescription
BrandSofokast
ManufacturerNatco Pharma Ltd
FormTablet
Shelf life2 years
Therapeutic UsesHepatitis C virus infection ( HCV)
We are manfacturer,trader & supplier of Sofokast Tablets. Sofokast tablet contains sofosbuvir 400mg an anti viral agent known as Sofosbuvir The anti-viral agents is most probably used for treating chronic hepatitis C viral infection caused by genotypes I, II, III or IV. Sofokast fixed dose combination structural protein inhibitors like NS5B.
INDICATION

Sofokast contains an anti viral agent known as Sofosbuvir The anti-viral agents is most probably used for treating chronic hepatitis C viral infection caused by genotypes I, II, III or IV. Sofokast fixed dose combination structural protein inhibitors like NS5B.

ADME

 

Absorption :
The peak plasma concentration time of Sofosbuvir is 0.5 to 1 hour
Distribution :
Sofosbuvir plasma protein binding capacity 61 to 65%
Metabolism :
The metabolism of both Sofokast  is occurs hepatically Sofosbuvir: cathepsin A, carboxyl esterase 1 or HINT1
Elimination :
Half life of Sofosbuvir is 0.4 hour & GS-331007: 27 hours Sofosbuvir: 80% through urine, 14% through feces.
SOFOKAST CAUSES UNDESIRABLE EFFECTS 

Headache Fatigue Nausea Asthenia Insomnia Anemia HBV reactivation Elevation of lipase & amylase levels Elevation of creatine kinase Cardiac disorder like bradycardia while concomitant with amiodarone Angioedema Skin rashes



Additional Information:

  • Production Capacity: Large
  • Delivery Time: Immediate
  • Packaging Details: 28 Tablets in a Bottle

View Complete details

get quoterequest a call back
Dacikast-60 Tablets.Daclatasvir 60mg

Dacikast-60 Tablets.Daclatasvir 60mg

Rs 1,500  / BottleGet Best Price

Minimum Order Quantity: 1 Bottle

Packaging Size1x28
Strength60mg
CompositionDaclatasvir 60mg
TreatmentHepatitis C virus infection (HCV)
Prescription/Non prescriptionPrescription
BrandDacikast-60
ManufacturerNatco Pharma Ltd
FormTablet
Shelf life2 years
Therapeutic UsesHepatitis C virus infection (HCV)
We are manfacturer,trader & supplier of Dacikast-60 tablet. Dacikast-60 tablet contains daclatasvir 60mg is an anti-viral medication which is used for preventing the disease progression of hepatitis C viral infection by reduces the multiplication of virus in the body. Dacikast-60 is used by combining with other anti-virals for treating the HCV infection in chronic stage majorly in adults. Dacikast-60 is usually combined with Sofosbuvir, with or without ribavirin.
CATEGORY

Dacikast-60 is belongs to class like;
Anti-hepaciviral drug
HCV NS5A protein inhibitor

MECHANISM

 

Dacikast-60 is a NS5A protein inhibitor, NS5A is a HCV non structural phosphoprotein that is responsible for replicating function of charge of viral RNA augmentation on endoplasmic reticulum membranes. Dacikast-60  has ability to merge to viral RNA. There are two pathway involved in the mechanism of Mydekla; Cis acting function of basally phosphorylated NS5A is responsible for maintaining the HCV replication complex. HCV assembly & infectious particle formation is altered by Trans acting function of hyperphosphorylated NS5A. Dacikast-60  is used to confuse the hyperphosphorylated NS5A proteins thus concludes as interceding with activity of newly produced HCV. Dacikast-60  works as blockade of; Intercellular viral RNA synthesis Virion assembly/ secretion in-vivo
SIDE EFFECTS OF  Dacikast-60

While using the drug Some common side effects occurred as follows:: Chest pain, dizziness Irregular heart beat Unusual tiredness More common: Headache, nausea Pharmacological effects:

 

OTHER

Pyrexia , hot flush, loss of weight, Fatigue, asthenia, influenza like symptoms

NERVE

Headache, migraine, somnolence

DERMATOLOGICAL

Rashes, Pruritus, dry skin, alopecia, and Erythema multiforme

PSYCHIATRIC

Insomnia, irritability, depression, anxiety

BLOOD

Anemia, neutropenia, thrombocytopenia, esinophillia

RESPIRATORY

Cough, Nasopharyngitis, dyspnea, nasal congestion, upper respiratory infection

GIT

Gastro esophageal reflux, vomiting, Abdominal pain, elevated lipase, flatulence

MUSCLE

Myalgia, arthralgia, back pain

METABOLIC

Loss of appetite

CVS

Bradycardia, heart block, cardiac arrhythmias

LIVER

Increased AST & ALT, Hyperbilirubinaemia, hepatitis B reactivation

GENITOURINARY

Urinary tract infection

OCULAR

Dry eye



Additional Information:

  • Production Capacity: Large
  • Delivery Time: Immediate
  • Packaging Details: 28 tablets in a bottle

View Complete details

get quoterequest a call back

EXPLORE MORE CATEGORIES